Menopur

Menotrophin, the active ingredient in Menopur, is a gonadotropin presented as a injectable solution for intramuscular and subcutaneous use. It treats infertility due to anovulation, supports controlled ovarian stimulation for assisted reproductive technologies, and addresses hypogonadotropic hypogonadism.

GNH USA supplies Menopur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Menopur, a gonadotropin used in reproductive endocrinology, is indicated for: - Infertility due to anovulation: stimulates follicular development to induce ovulation. - Controlled ovarian stimulation for assisted reproductive technologies (e.g., IVF): supports multiple follicle growth to improve egg retrieval. - Hypogonadotropic hypogonadism: provides FSH and LH activity to initiate and maintain ovarian function.

Menopur may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site reactions: pain, redness, or swelling at the injection site. - Mild ovarian hyperstimulation syndrome: abdominal discomfort, bloating, or mild weight gain. - Nausea or vomiting. - Headache.

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome: rapid weight gain, shortness of breath, or fluid accumulation. - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Allergic reactions: rash, urticaria, or anaphylaxis.

Before using Menopur, clinicians should consider several safety precautions. - Patient selection: assess ovarian reserve and baseline hormone levels. - Monitoring: perform regular ultrasound and estradiol measurements during stimulation. - Risk of OHSS: discontinue or adjust dose if signs of ovarian hyperstimulation appear. - Pregnancy testing: confirm negative pregnancy before initiating therapy. - Contraindications: avoid in patients with active ovarian cysts or uncontrolled thyroid disease. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menopur can interact with other medications that affect ovarian response or hormone metabolism.

Major Interactions (Avoid): - GnRH antagonists: may blunt the intended ovarian stimulation. - High‑dose estrogen therapy: can interfere with follicular development.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): increased risk of bleeding with OHSS‑related vascular changes. - Thyroid hormone replacement: dose adjustments may be needed due to altered hormone levels. - Steroid hormones (e.g., corticosteroids): may affect response to stimulation.